ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A bill that would reauthorize FDA to collect fees from manufacturers of animal drugs cleared Congress last week. The Animal Drug & Animal Generic Drug User Fee Reauthorization Act of 2013 (S. 622) now awaits the President’s signature to become law. FDA relies on user fees to supplement its annual congressionally approved appropriations. Such fees have enabled FDA to reduce its review time for new animal drugs and bring medications to market faster. The bill would allow FDA to collect more than $30 million in fees from the animal drug industry. The House of Representatives on June 3 and the Senate on May 8 both passed the bill without amendments, despite pressure from public health advocacy groups for a provision that would have required FDA to track the sale and use of antibiotics in animals.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X